Coenzyme Q10 ameliorates oxidative stress and prevents mitochondrial alteration in ischemic retinal injury

Dongwook Lee · Keun-Young Kim · Myoung Sup Shim · Sang Yeop Kim · Mark H. Ellisman · Robert N. Weinreb · Won-Kyu Ju

Published online: 12 December 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract Coenzyme Q10 (CoQ10) acts by scavenging reactive oxygen species for protecting neuronal cells against oxidative stress in neurodegenerative diseases. We tested whether a diet supplemented with CoQ10 ameliorates oxidative stress and mitochondrial alteration, as well as promotes retinal ganglion cell (RGC) survival in ischemic retina induced by intraocular pressure elevation. A CoQ10 significantly promoted RGC survival at 2 weeks after ischemia. Superoxide dismutase 2 (SOD2) and heme oxygenase-1 (HO-1) expression were significantly increased at 12 h after ischemic injury. In contrast, the CoQ10 significantly prevented the upregulation of SOD2 and HO-1 protein expression in ischemic retina. In addition, the CoQ10 significantly blocked activation of astroglial and microglial cells in ischemic retina. Interestingly, the CoQ10 blocked apoptosis by decreasing caspase-3 protein expression in ischemic retina. Bax and phosphorylated Bad (pBad) protein expression were significantly increased in ischemic retina at 12 h. Interestingly, while CoQ10 significantly decreased Bax protein expression in ischemic retina, CoQ10 showed greater increase of pBad protein expression. Of interest, ischemic injury significantly increased mitochondrial transcription factor A (Tfam) protein expression in the retina at 12 h, however, CoQ10 significantly preserved Tfam protein expression in ischemic retina. Interestingly, there were no differences in mitochondrial DNA content among control- or CoQ10-treated groups. Our findings demonstrate that CoQ10 protects RGCs against oxidative stress by modulating the Bax/Bad-mediated mitochondrial apoptotic pathway as well as prevents mitochondrial alteration by preserving Tfam protein expression in ischemic retina. Our results suggest that CoQ10 may provide neuroprotection against oxidative stress-mediated mitochondrial alterations in ischemic retinal injury.

Keywords Coenzyme Q10 · Retinal ischemia · Retinal ganglion cell · Oxidative stress · Mitochondrial transcription factor A · Mitochondrial DNA

Introduction

Elevated intraocular pressure (IOP) is an important risk factor for retinal ganglion cell (RGC) death and optic nerve degeneration in retinal ischemia and glaucoma [1]. Growing evidence indicates that ischemic injury by acute IOP elevation alters mitochondrial dynamics-related proteins and induces mitochondrial dysfunction-mediated apoptotic
cell death in the retina of rodent models [2, 3]. Importantly, our previous studies demonstrated that IOP elevation triggered release of mitochondrial fusion protein optic atrophy 1 and increase of mitochondrial fission GTPase dynamin related protein-1, as well as induced apoptotic cell death by modulating Bax/phosphorylated Bad (pBad) protein expression in ischemic retina [2, 3]. Collectively, these findings suggest that ischemic injury induced by acute IOP elevation is associated with mitochondrial dysfunction-mediated apoptotic pathway in the retina.

Oxidative stress has been implicated as an important pathophysiological mechanism for mitochondrial dysfunction-mediated retinal neurodegeneration including ischemic injury [4-7]. Superoxide dismutases (SODs), cytosolic SOD1 and mitochondrial SOD2, are expressed in the ganglion cell layer (GCL) and inner plexiform layer in rodent retina [8]. A recent study suggests that SOD2 has a protective role against oxidative stress-mediated neuronal cell death [9]. Of interest, we found that acute IOP elevation significantly increased SOD2 protein expression in the early neurodegeneration of ischemic rat retina [5]. In addition, increasing evidence indicates that oxidative stress is associated with mitochondrial DNA (mtDNA) alteration-related mitochondrial dysfunction in retinal neurodegeneration [5, 7, 10, 11]. However, it remains unknown whether oxidative stress induced by acute IOP elevation causes mtDNA alteration in ischemic retinal injury.

Mitochondrial transcription factor A (Tfam, also as known as mtTFA), a nucleus encoded DNA-binding protein in mitochondria, has an important role in mitochondrial gene expression and mtDNA maintenance, and therefore is essential for oxidative phosphorylation (OXPHOS)-mediated adenosine triphosphate (ATP) synthesis [12-15]. Mice lacking Tfam have impaired mtDNA transcription and loss of mtDNA leads to bioenergetics dysfunction and embryonic lethality [12]. In contrast, overexpression of Tfam mediates delayed neuronal death following transient forebrain ischemia in mice [16-18] as well as neonatal hypoxic-ischemic brain injury rapidly increased Tfam and OXPHOS complex IV protein expression in a rat model [19]. This suggests that these responses may support endogenous repair mechanisms for mtDNA damage following hypoxic-ischemic brain injury [19]. Of note, acute IOP elevation significantly increased Tfam and OXPHOS complex protein expression in the early neurodegeneration of ischemic rat retina [5], collectively suggesting that these responses may reflect endogenous repair mechanisms for elevated IOP-induced mitochondrial alteration in ischemic injury.

Coenzyme Q10 (CoQ10), an essential cofactor of the electron transport chain, acts by maintaining the mitochondrial membrane potential, supporting ATP synthesis and inhibiting reactive oxygen species (ROS) generation for protecting neuronal cells against oxidative stress in neurodegenerative diseases [20-22]. Previous studies have demonstrated that CoQ10 protected retinal neurons against hydrogen peroxide-induced oxidative stress in vitro [23] as well as prevented retinal damage caused by acute high IOP-induced transient ischemic injury [24, 25].

In the current study, we tested whether a diet supplemented with CoQ10 ameliorates oxidative stress-mediated apoptotic cell death in RGC degeneration by preventing mitochondrial alteration in ischemic mouse retina.

Materials and methods

Animals

Female, 4-month-old C57BL/6 mice (20-25 g in weight; The Jackson Laboratories, Bar Harbor, ME, USA) were housed in covered cages, fed with a standard rodent diet ad libitum, and kept on a 12 h light/12 h dark cycle. All procedures concerning animals were performed in accordance with the ARVO statement for the Use of Animals in Ophthalmic and Vision Research and under protocols approved by institutional IACUC committees at the University of California San Diego.

Induction of transient retinal ischemia

The mice were anesthetized with a mixture of ketamine (100 mg/kg, Ketaset; Fort Dodge Animal Health, Fort Dodge, IA, USA) and xylazine (9 mg/kg, TranquIved; Vedeco, Inc., St. Joseph, MO, USA) by intraperitoneal (IP) injection. Eyes were also treated with 1 % proparacaine drops. A 30-gauge needle was inserted into the anterior chamber of right eye that was connected by flexible tubing to a saline reservoir. By raising the reservoir, IOP was elevated to 70-80 mmHg for 50 min. Sham treatment was performed in the contralateral eyes by the insertion of a needle in the anterior chamber without saline injection. Retinal ischemia was confirmed by observing whitening of the iris and loss of the retina red reflex. IOP was measured with a tonometer (TonoLab; Tiolatoy, Helsinki, Finland) during ischemia. Non-ischemic contralateral control retinas were used as control.

Pharmacological treatment

CoQ10 was purchased from Kaneka Nutrients (Pasadena, TX, USA) or Sigma (St. Louis, MO, USA). AIN-93G purified control or a diet supplemented with CoQ10 were formulated by Harlan Laboratories (Madison, WI, USA). Four groups of mice were studied: a group of non-ischemic C57BL/6 mice treated with control diet (n = 20 mice), a
group of ischemic C57BL/6 mice treated with control diet (n = 30 mice), a group of non-ischemic C57BL/6 mice treated with 1% CoQ_{10} diet [(v/v), which equals a daily dose of 1,600–2,000 mg/kg body weight in 25–30 g mice, n = 20 mice] [26] and a group of ischemic C57BL/6 mice treated with 1% CoQ_{10} diet (n = 30 mice).

Tissue preparation

Six to 24 h after acute IOP elevation, light adapted mice were anesthetized with IP injection of mixture of ketamine/xylazine, as described, and then mice were perfused transecendally with 0.9% saline followed by 4% paraformaldehyde in 1X phosphate buffer saline (PBS, pH 7.4). Both eyes enucleated and fixed in 4% paraformaldehyde in 1X phosphate buffer saline (PBS, pH 7.4). Both eyes enucleated and fixed in 4% paraformaldehyde in 1X phosphate buffer saline (PBS, pH 7.4). Both eyes enucleated and fixed in 4% paraformaldehyde in 1X phosphate buffer saline (PBS, pH 7.4). Both eyes enucleated and fixed in 4% paraformaldehyde in 1X phosphate buffer saline (PBS, pH 7.4).

Whole-mount immunohistochemical analysis

Retinas from enucleated eyes were dissected as flattened whole-mounts at 12 h or 2 weeks after ischemia–reperfusion. Retinas were immersed in PBS containing 30% sucrose for 24 h at 4°C. The retinas were blocked in PBS containing 3% donkey serum, 1% bovine serum albumin, 1% fish gel and 0.1% Triton X-100 for 1 h, and incubated with goat polyclonal anti-Brn3a antibody (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), a specific maker for RGCs [28, 29], and guinea pig polyclonal anti-GFAP antibody (1:500; Advanced ImmunoChemical, Long Beach, CA, USA) for 3 days at 4°C. After several wash steps, the retinas were incubated with the secondary antibodies, Alexa Fluor-568 donkey anti-goat IgG antibody or Cy5-conjugated anti-guinea pig IgG antibody (Invitrogen, Carlsbad, CA, USA) for 24 h, and subsequently washed with PBS. The retinas were counterstained with the nucleic acid stain Hoechst 33342 (Invitrogen) in PBS. Images were captured under fluorescence microscopy (Eclipse microscope, model E800; Nikon instruments Inc., Melville, NY, USA) equipped with a digital camera (SPOT; Diagnostic Instrument, Sterling Heights, MI, USA). Images were acquired with commercial software (Simple PCI version 6.0 software; Compix Inc., Cranberry Township, PA, USA).

Quantitative analysis for RGC counting

To count RGCs labeled with Brn3a, each retinal quadrant was divided into three zones by central, middle, and peripheral retina [one sixth (~400 μm), three sixths (~1,200 μm), and five sixths (~2,000 μm) of the retinal radius from the optic nerve head]. Images were taken at 20×, covering an area of 0.344 mm², and then the number of RGCs were normalized per mm². RGC densities were measured in 24 distinct areas (two areas at central, middle, and peripheral per retinal quadrant) per condition by two investigators in a masked fashion, and the scores were averaged (n = 7 retinas/group). To further examine RGC survival between control and CoQ_{10} diet-treated non-ischemic retinas, RGC densities were automatically measured using ImageJ cell counting analysis (http://rsb.info.nih.gov/ij/, National Institute of Health, Bethesda, MD, USA).

Immunohistochemical analysis

Immunohistochemical staining of retinal cross sections at 12 h after transient ischemia was performed as previously described [27]. Five sections per wax block from each group were used for immunohistochemical analysis. Primary antibodies were goat polyclonal anti-Brn3a antibody (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), a specific maker for RGCs [30], monoclonal mouse anti-GFAP antibody (1:500; Sigma, St. Louis, MO, USA) and rabbit polyclonal anti-Iba1 antibody (1:500; Wako Chemicals USA, Inc., Richmond, VA, USA). To prevent non-specific background, tissues were incubated in 1% bovine serum albumin/PBS for 1 h at room temperature before incubation with the primary antibodies for 16 h at 4°C. After several wash steps, the tissues were incubated with the secondary antibodies, Alexa Fluor 568 dye-conjugated donkey anti-goat IgG antibody (Invitrogen, Carlsbad, CA, USA), Cy5 dye-conjugated goat anti-mouse IgG antibody (Invitrogen) or Alexa Fluor 488 dye-conjugated anti-rabbit IgG antibody (1:100; Invitrogen) for 4 h at 4°C and subsequently washed with PBS. The sections were counterstained with the nucleic acid stain Hoechst 33342 (Invitrogen) in PBS. Images were acquired with confocal microscopy (Olympus Fluoview1000; Olympus, Tokyo, Japan).

Western blot analysis

Following 6, 12 or 24 h after transient ischemia, the collected retinas were homogenized in a glass-Teflon Potter homogenizer in RIPA lysis buffer (150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, 1 mM DTT, 0.5% sodium deoxycholate and 50 mM Tris-Cl, pH 7.6) containing complete protease inhibitors (Roche Biochemicals, Indianapolis, IN, USA). Each sample (10 μg; n = 3 retinas/group) was separated by PAGE and electrotransferred to polyvinylidene difluoride membrane. The membrane was blocked with 5% nonfat dry milk and 0.1% Tween-20 in PBS for 1 h, incubated with rabbit polyclonal anti-SOD2
antibody (1:5000; Santa Cruz Biotechnology), rabbit polyclonal anti-HO-1 antibody (1:1000; Millipore), monoclonal mouse anti-GFAP (1:3000; Sigma), rabbit polyclonal anti-lba-1 antibody (1:2000; Wako Chemical USA), mouse monoclonal anti-caspase antibody (1:3000; Cell Signaling, Danvers, MA, USA), rabbit polyclonal anti-Bax antibody (1:500; Santa Cruz Biotechnology), mouse monoclonal anti-phosphorylated Bad (pBad, 1:2000; Cell Signaling), goat polyclonal anti-Tfam antibody (1:1000; Santa Cruz Biotechnology), rabbit polyclonal anti-Porin (1:1000; Calbiochem, La Jolla, CA, USA) and mouse monoclonal anti-actin antibody (1:10,000, Millipore, Billerica, MA, USA) for overnight at 4 °C. After several washes in Tween/PBS, the membranes were incubated with peroxidase-conjugated donkey anti-goat IgG (1:5000; Bio-Rad, Hercules, CA, USA) or goat anti-rabbit IgG (1:5000; Bio-Rad) and goat anti-mouse IgG (1:5000; Bio-Rad), and developed using chemiluminescence detection (ECL Plus; GE Healthcare Bio-Science, Piscataway, NJ, USA). The scanned film Images were analysed by ImageJ (National Institute of Health) and band densities were normalized to the band densities for actin or porin.

TUNEL staining

The retinal cross sections at 12 h after transient ischemia were incubated with proteinase K (10 μg/mL, 10 mM Tris, pH 7.4–8.0) for 10 min at 37 °C. After rinsing in PBS, the sections were incubated with terminal deoxynucleotidyl transferase plus nucleotide mixture in reaction buffer for 60 min at 37 °C (In situ Cell Death Detection kit, Roche Applied Science, Indianapolis, IN, USA) as previously described [3]. To count TUNEL-positive cells, the areas were divided into three layers by GCL, inner nuclear layer (INL) and outer nuclear layer (ONL). TUNEL-positive cells were counted in eight microscopic fields of 0.2 mm from retinal sections per condition (n = 5 retinas/group) by two investigators in a masked fashion, and the scores were averaged.

Measurement of mtDNA content

MtDNA content of each sample at 12 h after transient ischemia was determined as described previously [31]. Briefly, total genomic DNA (gDNA) was isolated from retinas by using DNeasy® Blood & Tissue Kit (Qiagen, Valencia, CA, USA) as described in the manufacturer’s protocol. For the measurement of relative mtDNA content, real-time PCR was carried out using MX3000P real-time PCR system (Stratagene, La Jolla, CA, USA) as following. Total gDNAs (10 ng) from each sample were amplified using iQTM SYBR® Green supermix (Bio-Rad, Hercules, CA, USA) and mitochondrial cytochrome B (CytB-F: 5'-GGTCTTTTCTTAGCCATACACTACA-3'; CytB-R: 5'-ATATCGGATTAGTCACCGTGTAAT-3') or β-actin (ActB-F: GATCGATGCCGGTGCTAAGA-3'; ActB-R: 5'-CACCATCACCCCTGTGGAAG-3') primers for 40 cycles [initial incubation at 95 °C for 10 min, and 40 cycles (95 °C for 30 s, 55 °C for 30 s and 72 °C for 20 s)]. Output data were obtained as Ct values and the difference of mtDNA content among samples was calculated using the comparative Ct method [32]. ActB gene was used to normalize the ratio between mtDNA and gDNA. The samples were run in triplicates for all experiment.

Statistical analysis

Data were presented as the mean ± SD. Comparison of two or three experimental conditions was evaluated using the unpaired, two-tailed Student’s t test or one-way analysis of variance and the Bonferroni t test. P < 0.05 was considered to be statistically significant.

Results

The effect of CoQ10 in IOP and body weight

We began either unsupplemented control or CoQ10 (1 %)-supplemented diet treatment daily for 1 week before the induction of transient retinal ischemia and then continued diet treatment for 2 weeks (Fig. 1a). Transient retinal ischemia was induced by acute IOP elevation to 71.8 ± 4.0 mmHg in mice treated with control diet (n = 30 mice) and 70.3 ± 5.0 mmHg in mice treated with CoQ10 diet (n = 30 mice) for 50 min (Fig. 1b). The pressure was enough to induce retinal ischemia and the phenotype was similar to pathologic acute angle closure glaucoma because when IOP reached 60 mmHg, the retina flow rate decreased by 68 % for retinal artery in rodent model [5, 33, 34]. The mean IOP of contralateral control eyes was 8.4 ± 0.7 mmHg (n = 20 mice; Fig. 1b). In addition, no difference was found in body weight between control and CoQ10 diet-treated mice during experimental period (n = 20 or 30 mice; Fig. 1b).

CoQ10 ameliorates oxidative stress in ischemic retina

We determined whether CoQ10 treatment prevents oxidative stress-mediated upregulation of superoxide dismutase 2 (SOD2) and heme oxygenase-1 (HO-1) protein expression using antibodies raised against SOD2 and HO-1. We observed that Increase of SOD2 protein expression was maximal 12 h later by 1.36 ± 0.04-fold in ischemic retina (P < 0.05; Fig. 2a). The relative quantity of SOD2 protein expression was less at 24 h than at 12 h after
ischemia–reperfusion. Intriguingly, CoQ10 treatment preserved SOD2 and HO-1 protein expression in ischemic retina at 12 h compared with control diet-treated ischemic retina (P < 0.05; Fig. 2b), indicating that CoQ10 ameliorates oxidative stress in ischemic retinal injury.

CoQ10 promotes RGC survival in ischemic retina

Since CoQ10 is neuroprotective against retinal damage by high IOP-induced transient ischemic injury and other apoptotic insults [35, 36], we determined whether CoQ10 promotes RGC survival in ischemic retina using whole-mount immunohistochemistry for Brn3a, a marker for RGCs. Mean RGC density per retina for each group is presented in Supplementary Table 1. Non-ischemic control mouse retina had an average of 3329 ± 533 RGCs in the central, 3326 ± 446 RGCs in the middle and 2230 ± 420 RGCs in the peripheral areas (n = 7 retinas) (Fig. 3a, b; Supplementary Table 1). In comparison with non-ischemic control retina treated with control diet, control diet treatment showed about 32 % of RGC loss in ischemic retina (P < 0.01; Fig. 3a, b; Supplementary Table 1). In contrast, CoQ10 significantly promoted RGC survival by an approximate 21 % compared with control diet-treated ischemic retina (P < 0.05; Fig. 3a, b; Supplementary Table 1). Astroglial and/or microglial activation coincide with RGC degeneration in the hypertensive retina of human, rat or mouse (3, 37–39). To investigate whether CoQ10 blocks the activation of astroglial and microglial cells in ischemic retina, we performed whole-mount immunohistochemistry or Western blot analyses using antibodies raised against glial fibrillary acidic protein (GFAP), a marker for astroglial cells, or Iba1, a marker for microglial cells. We found that GFAP and Iba1 immunoreactivity were increased in activated astroglia and microglial cells in the GCL and nerve fiber layer of control diet-treated ischemic retina at 12 h, respectively (Fig. 4a). Further, astroglial and microglial activation are accompanied by RGC loss as indicated by significantly increased GFAP and Iba-1 protein expression by 2.89 ± 0.49- and 11.8 ± 2.59-fold in control diet-treated ischemic retina at
To determine whether CoQ10 prevents apoptotic cell death in ischemic retina, we performed TUNEL staining. There were no TUNEL-positive cells in the retina of control mice treated control diet (Fig. 5a, b). However, ischemic retinas showed TUNEL-positive apoptotic cell death in the inner nuclear layer (58 ± 10 per mm) and GCL (99 ± 18 per mm) at 12 h (Fig. 5a, b). In contrast, there were no TUNEL-positive cells in ischemic retina treated CoQ10 diet (Fig. 5a, b). In comparison with control diet-treated non-ischemic control retina, control diet-treated ischemic retina showed a significant induction of cleaved caspase-3 protein expression at 12 h by 2.68 ± 0.29-fold (P < 0.01; Fig. 5c). However, CoQ10 significantly reduced cleaved caspase-3 protein expression at 12 h by 0.98 ± 0.21-fold in ischemic retina (P < 0.01; Fig. 5c).

Our previous study showed that ischemic injury induces a significant increase of Bax and pBad protein expression in the early apoptotic pathway-mediated neurodegeneration of rat retina [5]. To determine whether CoQ10 modulates apoptotic cell death pathway in ischemic retina, we performed Western blot analysis using antibodies for Bax and pBad. We found that Bax protein expression was significantly increased by 2.71 ± 0.25-fold in ischemic retina at 12 h compared with control diet-treated non-ischemic control retina (P < 0.01; Fig. 6). In contrast, CoQ10 significantly decreased Bax protein expression by 1.61 ± 0.15-fold in ischemic retina at 12 h compared with control diet-treated ischemic retina (P < 0.01; Fig. 6). pBad protein expression was significantly increased by 8.02 ± 0.56-fold in ischemic retina at 12 h compared with control diet-treated non-ischemic control retina (P < 0.01; Fig. 6). Intriguingly, CoQ10 showed greater increase of pBad protein expression by 9.31 ± 0.39-fold in ischemic retina at 12 h compared with control diet-treated ischemic retina (P < 0.05; Fig. 6), suggesting that CoQ10 protects RGCs against oxidative stress-mediated apoptotic cell death by decreasing Bax or by increasing pBad protein expression in ischemic retina.

CoQ10 preserves Tфam protein expression in ischemic retina

To determine whether oxidative stress induced by acute IOP elevation alters mtDNA content and whether CoQ10 preserves this alteration in ischemic retina, mtDNA content was determined by real-time PCR analysis. We found that there were no differences in mtDNA content among control diet-treated non-ischemic control, and control diet-treated ischemic and CoQ10-treated ischemic retinas at 12 h (Fig. 7a). Oxidative stress triggers increase of Tfam protein expression in ischemic rat retina [5]. To determine whether CoQ10 preserves this alteration in ischemic retina, we examined the expression level of Tfam using Western blot analysis. We observed that Increase of Tfam protein expression was maximal 12 h later by 1.86 ± 0.12-fold in ischemic retina (P < 0.05; Fig. 7b). The relative expression level of Tfam protein was less at 24 h than at 12 h in ischemic retina. Intriguingly, CoQ10 treatment partially preserved Tfam protein expression at 12 h compared with control diet-treated ischemic retina (P < 0.05; Fig. 7c).
Fig. 4 CoQ10-mediated blockade of astroglial and microglial activation in ischemic retina.

Unsupplemented control or CoQ10 (1 %) diet were daily treated for 1 week before the induction of transient retinal ischemia and continued for 12 h.

(a) Double immunohistochemistry for GFAP and Iba-1 at 12 h after transient retinal ischemia. Control diet-treated ischemic retina increased GFAP and Iba-1 immunoreactivities in the GCL compared with control diet-treated non-ischemic control retina. In contrast, CoQ10 treatment decreased GFAP and Iba1 immunoreactivities in the GCL of ischemic retina. Intriguingly, higher magnification showed a quiescent microglial cell that has ramified long and thin processes in control diet-treated non-ischemic control retina and CoQ10 diet-treated ischemic retina (arrowheads). However, control diet-treated ischemic retina showed an activated microglial cell that has thickened processes (arrowheads) and swollen cell body (arrow). GCL, ganglion cell layer. Scale bars 50 μm.

(b) GFAP and Iba-1 Western blot analyses at 12 h after transient retinal ischemia. Control diet-treated ischemic retina significantly increased GFAP and Iba-1 protein expression compared with control diet-treated non-ischemic control retina. However, CoQ10 treatment significantly decreased GFAP and Iba-1 protein expression in ischemic retina. Values are mean ± SD (n = 3 retinas/group).

*Significant at P < 0.05 and **Significant at P < 0.01 compared with control diet-treated non-ischemic control retina or #Significant at P < 0.05 and ##Significant at P < 0.01 compared with control diet-treated ischemic retina.
However, there was no difference in expression level of porin protein between control diet- and CoQ10 diet-treated ischemic retina. These results suggest that oxidative stress induced by acute IOP elevation increases Tfam protein expression but shows no alteration of mtDNA content in ischemic retina.

Discussion

CoQ10 is an attractive neurotherapeutic agent for retinal protection against high IOP elevation-induced oxidative stress in retinal ischemic injury [24, 25] as well as other neurodegenerative diseases including Parkinson’s and Huntington’s diseases [20, 26, 40–42]. Moreover, CoQ10 is neuroprotective in retinal cells in vivo and in vitro against oxidative stress and excitotoxicity [23, 35, 41]. It has been reported that that CoQ10 supplements correlated with plasma CoQ10 level and CoQ10 in large doses was taken up all tissues including heart and brain mitochondria [43], suggesting that CoQ10 could also be taken up by retina and lead to a beneficial effect in ischemic retina injury. In support of this notion, a recent study demonstrated that oral supplementation of CoQ10 was neuroprotective against retinal damage induced by intravitreal injection of N-methyl-d-aspartate in mice in vivo [23]. In the current study, we addressed the question of whether a CoQ10-supplemented diet inhibits oxidative stress-mediated...
mitochondrial DNA in ischemic retina. *Tfam* protein expression was less at 24 h than at 12 h after ischemia–reperfusion. *Tfam* Western blot analysis at 12 h after transient retinal ischemia. Increase of *Tfam* protein expression was maximal at 12 h in control diet-treated ischemic retina. The relative concentration of *Tfam* protein expression was less at 24 h than at 12 h after ischemia–reperfusion.

We previously reported that acute IOP elevation triggers the upregulation of SOD2 protein expression and this increase could be restored by brimonidine (BMD)-mediated blockade of glutamate excitotoxicity-induced oxidative stress in ischemic rat retina [5]. Consistent with these results, we have now found that the upregulation of SOD2 and HO-1 protein expression by acute IOP elevation was maximal early the neurodegeneration (12 h) of retinal ischemia. However, CoQ10 treatment decreases SOD2 and HO-1 protein expression in ischemic retina. Endogenous antioxidants such as mitochondrial SOD2 that localizes in the mitochondrial matrix and catalyzes the dismutation of superoxide radicals normally regulate ROS generated in mitochondria [44, 45]. It has been reported that SOD2 expression is increased by the stimulation of mitochondrial superoxide anion (O$_2^-$) [46] and CoQ10 treatment could reduce the O$_2^-$ production [47]. Growing evidence indicates that overexpression of the SOD2 gene inhibits retinal damage by reducing oxidative stress and nitrosative stress [48], as well as protecting retinal vascular cells and capillary degeneration against apoptotic cell death in mouse models of ischemic injury [49]. Moreover, the upregulation of SOD2 is accompanied by a higher resistance to oxidative stress as well as SOD2 activity directly stabilizing mitochondrial transmembrane potential and calcium buffering ability [50, 51]. Our results, therefore, raise the possibility that increasing SOD2 or HO-1 expression in retinal ischemic injury may contribute to compensatory endogenous antioxidant mechanisms that increase resistance or stabilization of mitochondria against acute IOP elevation-induced oxidative stress. Taken together, it is noteworthy that these results suggest that CoQ10 could be an important antioxidant for ameliorating oxidative stress-mediated neurodegeneration in ischemic retina. Studying the benefits of CoQ10-mediated blockade of oxidative stress or enhancement of antioxidant enzymes may be a novel strategy for protecting retinal neurons against ischemic injury.

In the current study, we observed that CoQ10 treatment significantly promoted RGC survival as well as blocked activation of astrogial and microglial cells in ischemic retina. Astrogial or microglial activation coincides with RGC degeneration in the hypertensive retina of human, rat or mouse [3, 5, 37–39]. Thus, it is possible that CoQ10-mediated blockade of oxidative stress may indirectly reduce astrogial or microglial activation in the retina against elevated IOP-induced ischemic damage as a result of increased RGC survival. Regardless, it cannot be excluded that CoQ10 may prevent glial activation by blocking oxidative stress in astrogial or microglial cells in ischemic retina. CoQ10 is also neuroprotective in retinal glial cells against oxidative stress, since oxidative stress has remarkably linked to glial cell activation or reaction in the retina or optic nerve still needs to be ascertained [5, 52–56]. In addition, interestingly, it has been reported that IOP induced the upregulation of GFAP and major histocompatibility complex class II molecule, as well as of microglial activity in the contralateral control retinas in experimental rodent models of glaucoma induced by laser treatment [57, 58]. Although there was no evidence of glial activation in the contralateral non-ischemic control retina in the current study, future studies will need to clarify to use contralateral retina as an internal control in our ischemic model of mice.

Consistent with our result that CoQ10 promoted RGC survival in ischemic retina, we found that CoQ10 significantly decreased Bax, but increased pBad protein expression in ischemic retina. Bax is a pro-apoptotic member of the Bcl-2
family that is essential in many apoptotic pathways [59, 60] as well as directly interacts with the component forming the mitochondrial permeability transition pore (MPTP) that allows proteins to escape from the mitochondria into the cytosol to initiate apoptosis [61–63]. Bax is counteracted by Bcl-xL that forms heterodimers with dephosphorylation of Bad, which inactivates Bcl-xL; and pBad eliminates this dimerization, which activates Bcl-xL [64, 65].

Our collective results suggest that CoQ10 promotes RGC survival against the mitochondria-related apoptotic pathway in ischemic retinal injury by decreasing Bax, but by increasing pBad protein expression. These results reflect the possibility that increased pBad expression may represent an endogenous repair mechanism against apoptotic pathway and that CoQ10 may contribute to the blockade of Bax-mediated increase of MPT or the promotion of mitochondrial homeostasis in ischemic injury. The MPTP opening leads to loss of mitochondrial membrane potential, mitochondrial swelling, rupture of the outer mitochondrial membrane and release of cytochrome c. Importantly, MPTP opening by calcium overload and oxidative stress leads to necrosis rather than apoptosis [66, 67]. Recently, MPTP-mediated neuronal cell death has been implicated as an important pathophysiological mechanism for mitochondrial dysfunction in ischemic injury [24, 25].

Taken together, out findings suggest that CoQ10 may promote RGC survival by inhibiting not only apoptosis but also necrosis in ischemic retinal injury.

Ischemic injury triggers mitochondrial dysfunction including ROS induction as well as mtDNA damage, Tfam alteration or OXPHOS impairment in the central nervous system [5, 19, 68]. Recently, we have reported that acute IOP elevation significantly increased Tfam/OXPHOS complex protein expression and that blockade of glutamate excitotoxicity-induced oxidative stress by BMD treatment preserved Tfam/OXPHOS complex protein expression in ischemic retina [5], suggesting that the preservation of Tfam/OXPHOS complex may provide therapeutic potential for protecting RGCs against mitochondrial dysfunction induced by glutamate excitotoxicity and/or oxidative stress in ischemic retina [5]. In the current study, we observed that retinal ischemic injury triggers significant increase of Tfam protein expression in the early neurodegenerative events (6–12 h) and CoQ10 decreases Tfam protein expression in ischemic retina at 12 h. Emerging evidence suggests that the Tfam and OXPHOS complex IV are rapidly increased in the early neurodegenerative events of neonatal hypoxic-ischemic brain injury, suggesting that Tfam may contribute to endogenous repair mechanism of injured brain neurons [19].

Further, recent studies reported that overexpression of Tfam protects mitochondria against β–amyloid-induced oxidative damage in human SH-SY5Y neuroblastoma cells and ameliorates delayed neuronal cell death in the hippocampus following transient forebrain ischemia in mice [16, 17]. In contrast, in mice lacking Tfam there is impaired mtDNA transcription and mtDNA loss is triggered; this leads to mitochondrial bioenergetic dysfunction-mediated embryonic lethality [12].

Based on these results, we suggest that CoQ10-mediated preservation of Tfam expression may provide a potential mechanism for protecting RGCs against oxidative stress-induced mitochondrial dysfunction in ischemic retina. Future studies will examine the precise molecular mechanism underlying CoQ10-mediated Tfam preservation in ischemic retina. Although mtDNA is particularly susceptible to oxidative stress [69], it is unknown whether oxidative stress can directly trigger mtDNA alteration in ischemic retina. Interestingly, we found that there was no statistical difference in mtDNA content among control diet- and CoQ10 diet-treated groups. Because it has been reported that Tfam regulates mtDNA copy numbers in mammals and the levels of Tfam correlate with the levels of mtDNA [15, 70], our findings that did not show a correlation between Tfam protein expression and mtDNA content raise the possibility that increasing Tfam protein expression may prevent alteration of mtDNA content against oxidative stress in ischemic retina. Regardless, it would be useful to investigate mtDNA alteration on ischemic retina using measurements for 8-hydroxy-2-deoxyguanosine and mitochondrial membrane potential, and future studies need to address this more detail.

In conclusion, these results provide direct evidence that CoQ10 promotes RGC survival in ischemic mouse retina by inhibiting oxidative stress and by blocking the Bax/Bad-mediated mitochondrial apoptotic pathway. Moreover, CoQ10 also preserves Tfam protein expression in ischemic mouse retina. Based on these observations, we suggest that CoQ10 may provide a promising therapeutic potential for ameliorating oxidative stress-mediated mitochondrial dysfunction in ischemic retinal injury.

Acknowledgments This work was supported, in part, by the National Institute Health Grants EY018658 (WKJ), NCRR P41 RR004050 and P41GM103412-24 (MHE) and P30EY022589 (Vision Research Core Grant), and a fund of Biomedical Research Institute of Chonbuk National University Hospital (DL) and an unrestricted grant from Research to Prevent Blindness (New York, NY, USA).

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Weinreb RN, Khaw PT (2004) Primary open-angle glaucoma. Lancet 363:1711–1720
2. Ju WK, Lindsey JD, Angert M, Patel A, Weinreb RN (2008) 
Glutamate receptor activation triggers OPA1 release and induces 
apoptotic cell death in ischemic rat retina. Mol Vis 14:2629–2638

3. Park SW, Kim KY, Lindsey JD, Heo H, Nguyen DH, Ellisman 
MH et al (2011) A selective inhibitor of drp1, mdivi-1, increases 
retinal ganglion cell survival in acute ischemic mouse retina. 
Invest Ophthalmol Vis Sci 52:2837–2843

4. Chan AS, Saraswathy S, Relah K, Ueki M, Rao NA (2012) 
Neuroglobin protection in retinal ischemia. Invest Ophthalmol 
Vis Sci 53:704–711

5. Lee D, Kim KY, Noh YH, Chai S, Lindsey JD, Ellisman MH et al 
(2012) Brimonidine blocks glutamate excitotoxicity-induced 
oxidative stress and preserves mitochondrial transcription factor 
a in ischemic retinal injury. PLoS One 7:e47098

6. Liu J, Ju WK, Crowston JG, Xie F, Perry G, Smith MA et al 
(2007) Oxidative stress is an early event in hydrostatic pressure 
induced retinal ganglion cell damage. Invest Ophthalmol Vis Sci 
48:4580–4589

7. Kong YK, Van Bergen N, Trounce IA, Bui BV, Chrysostomou V, 
Waugh H et al (2011) Increase in mitochondrial DNA mutations 
impairs retinal function and renders the retina vulnerable to 
aging. Aging Cell 10:572–583

8. Oguni M, Tanaka O, Tamura H, Shinhara H, Kato K, Setogawa T 
(1995) Ontogeny of copper-zinc and manganese superoxide 
dismutase in the developing rat retina: immunohistochemical and 
immunohematochemical study. Ophthalmic Res 27:227–233

9. Fukui M, Zhu BT (2010) Mitochondrial superoxide dismutase 
SOD2, but not cytosolic SOD1, plays a critical role in protection 
against glutamate-induced oxidative stress and cell death in HT22 
neuronal cells. Free Radic Biol Med 48:821–830

10. Jarrett SG, Lin H, Godley BF, Boulton ME (2008) Mitochondrial 
DNA damage and its potential role in retinal degeneration. Prog 
Retin Eye Res 27:596–607

11. Lee S, Van Bergen NJ, Kong GY, Kong GY, Chrysostomou V, 
Waugh HS et al (2011) Mitochondrial dysfunction in glaucoma 
and emerging bioenergetic therapies. Exp Eye Res 93:204–212

12. Larsson NG, Wang J, Wilhelmsson H, Oldfors A, Rustin P, 
Lewandoski M et al (1998) Mitochondrial transcription factor A 
is necessary for mtDNA maintenance and embryogenesis in mice. 
Nat Genet 18:231–236

13. Bonavitz ND, Clayton DA, Shadel GS (2006) Initiation and 
beyond: multiple functions of the human mitochondrial tran-
scription factor A (TFAM) ameliorates delayed neuronal death due to 
transient forebrain ischemia in mice. Neuron Pathology 10: 
276:3800–3809

14. Falkenberg M, Larsson NG, Gustafsson CM (2007) DNA repli-
cation and transcription in mammalian mitochondria. Annu Rev 
Biochem 76:679–699

15. Ngo HB, Kaiser JT, Chan DC (2011) The mitochondrial trans-
cription and packaging factor Tfam imposes a U-turn on mito-
ochondrial DNA. Nat Struct Mol Biol 18:1290–1296

16. Xu S, Zhong M, Zhang L, Wang Y, Zhou Z, Hao Y et al (2009) 
Overexpression of Tfam protects mitochondria against beta-
amylloid-induced oxidative damage in SH-SY5Y cells. FEBS J 
276:3800–3809

17. Hokari M, Kuroda S, Kinugawa S, Ide T, Tsutsui H, Iwasaki Y 
(2010) Overexpression of mitochondrial transcription factor A 
(TFAM) ameliorates delayed neuronal death due to transient 
forebrain ischemia in mice. Neuropathology 30: 401–407

18. Piao Y, Kim HG, Oh MS, Pak YK (2012) Overexpression of 
TFAM, NRF-1 and myr-AKT protects the MPP(+)–induced 
mitochondrial dysfunctions in neuronal cells. Biochim Biophys 
Acta 1820:577–585

19. Yin W, Signore AP, Iwai M, Cao G, Gao Y, Chen J (2008) 
Rapidly increased neuronal mitochondrial biogenesis after hyp-
oxic-ischemic brain injury. Stroke 39:3057–3063

20. Beal MF, Shults CW (2003) Effects of Coenzyme Q10 in Hun-
tington’s disease and early Parkinson’s disease. Biofactors 
18:153–161

21. McCarthy S, Somayajulu M, Sikorska M, Borowoy-Borowski H, 
Pandey S (2004) Paraquat induces oxidative stress and neuronal 
cell death; neuroprotection by water-soluble Coenzyme Q10. 
Toxicol Appl Pharmacol 201:21–31

22. Bessler AC, Clarke PG (2010) Neuroprotection for optic nerve 
disorders. Curr Opin Neurol 23:10–15

23. Nakajima Y, Inokuchi Y, Nishi M, Shimazawa M, Otsubo K, 
Hara H (2008) Coenzyme Q10 protects retinal cells against 
oxidative stress in vitro and in vivo. Brain Res 1226:226–233

24. Russo R, Cavaliere F, Rombola L, Gliozzi M, Cerulli A, Nucci C et al (2008) Rational basis for the development of coenzyme Q10 
as a neurotherapeutic agent for retinal protection. Prog Brain Res 
173:575–582

25. Nucci C, Tartaglione R, Cerulli A, Mancino R, Spano A, Cavaliere F et al (2007) Retinal damage caused by high intraocular 
pressure-induced transient ischemia is prevented by coenzyme 
Q10 in rat. Int Rev Neurobiol 82:397–406

26. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ et al (2009) Combination therapy with coenzyme Q10 and 
creatine produces additive neuroprotective effects in models of 
Parkinson’s and Huntington’s diseases. J Neurochem 109:1427–1439

27. Ju WK, Misaka T, Kushnareva Y, Nakagomi S, Agarwal N, Kudo Y et al (2005) OPA1 expression in the normal rat retina and optic 
nerve. J Comp Neurol 488:1–10

28. Galindo-Romero C, Aviles-Trigueros M, Jimenez-Lopez M, 
Vallente-Soriano FJ, Sallinas-Navarro M, Nadal-Nicolas F et al 
(2011) Axotomy-induced retinal ganglion cell death in adult 
mice: quantitative and topographic time course analyses. Exp Eye 
Res 92:377–387

29. Galindo-Romero C, Valiente-Soriano FJ, Jimenez-Lopez M, 
Valiente-Soriano FJ, Sallinas-Navarro M, Nadal-Nicolas F et al (2013) Effect of brain-derived neurotrophic factor on mouse 
axotomized retinal ganglion cells and phagocytic microglia. 
Invest Ophthalmol Vis Sci 54:974–985

30. Nadal-Nicolas FM, Jimenez-Lopez M, Sobrado-Calvo P, Nieto-
Lopez L, Canovas-Martinez I, Salinas-Navarro M et al (2009) 
Bm3a as a marker of retinal ganglion cells: qualitative and 
quantitative time course studies in naive and optic nerve-injured 
retinas. Invest Ophthalmol Vis Sci 50:3860–3868

31. Alavi MV, Bette S, Schimpf S, Schuettauf F, Schraermeyer U, 
Toehl HF et al (2007) A splice site mutation in the murine Opal 
gene features pathology of autosomal dominant optic atrophy. 
Brain 130:1029–1042

32. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data 
by the comparative C(T) method. Nat Protoc 3:1101–1108

33. Zhi Z, Cepurna W, Johnson E, Shen T, Morrison J, Wang RK 
(2011) Volumetric and quantitative imaging of retinal blood flow 
in rats with optical microangiography. Biomed Opt Express 
2:579–591

34. Vallente-Soriano FJ, Salinas-Navarro M, Nadal-Nicolas F et al 
(2011) Axotomy-induced retinal ganglion cell death in adult 
mice: quantitative and topographic time course analyses. Exp Eye 
Res 92:377–387

35. McCarthy S, Somayajulu M, Sikorska M, Borowoy-Borowski H, 
Pandey S (2004) Paraquat induces oxidative stress and neuronal 
cell death; neuroprotection by water-soluble Coenzyme Q10. 
Toxicol Appl Pharmacol 201:21–31

36. Lulli M, Witort E, Papucci L, Torre E, Schiavone N, Dal Monte 
M et al (2012) Coenzyme Q10 protects retinal cells from apop-
tosis induced by radiation in vitro and in vivo. J Radiat Res 
53:695–703
